Enterobactin inhibits microbiota-dependent activation of AhR to promote bacterial sepsis in mice

Recent research published in Nature Microbiology investigates the biological mechanisms that differentiate sepsis survivors from non-survivors, moving beyond traditional immunology to include microbiome-driven factors. By studying mouse models and human clinical samples, the authors discovered that peritoneal macrophages in survivors exhibit a specific genetic signature that suppresses harmful inflammation. This protective state is heavily influenced by tryptophan metabolites and indoles, which activate the aryl hydrocarbon receptor (AhR) to regulate the host's immune response. The study demonstrates that treatments like fecal microbiota transplantation (FMT) can improve survival by restoring these beneficial microbial products. Furthermore, researchers identified specific bacterial compounds, such as enterobactin, that can interfere with this signaling pathway, highlighting a complex tug-of-war between the host and infecting pathogens. Ultimately, these findings suggest that the gut-immune axis plays a critical role in determining the severity and outcome of life-threatening infections.